 |
58 Diseases |  |
27 Trials |
|
27 Trials |  |
1449 News |  |
| «123456789101112 |
- oxycodone controlled release / Generic mfg.
Trial completion, Surgery: Safety and Tolerability of Controlled-release Oxycodone on Postoperative Pain in Oncologic Head and Neck Surgery (clinicaltrials.gov) - Apr 15, 2013
P=N/A, N=83, Completed, Sponsor: Instituto Nacional de Cancer, Brazil
Not yet recruiting --> Completed
- ||| oxycodone controlled release / Generic mfg.
Enrollment change: A Study to Evaluate Efficacy and Safety of Oxycodone/Naloxone Compared to OxyContin in Korean Cancer Patients (clinicaltrials.gov) - Mar 12, 2013
P4, N=128, Recruiting, Sponsor: Mundipharma Pte Ltd.
Not yet recruiting --> Completed N=170 --> 128
- | oxycodone controlled release / Generic mfg.
New P1 trial: A Randomized, Open-label, Multiple-dose, Two-sequence, Two-period Crossover Study to Investigate The Pharmacokinetics Between a GL2907 and Oxycontin CR Tab. 10mg in Healthy Male Volunteers (clinicaltrials.gov) - Jan 28, 2013
P1, N=24, Not yet recruiting, Sponsor: GL Pharm Tech Corporation
- | Palexia RP (tapentadol extended release) / Assertio, J&J, Grunenthal, Collegium Pharma
Trial termination: An Open-label Evaluation of Tapentadol Extended Release (ER) in Participants With Moderate to Severe Chronic Pain After Conversion From Hydrocodone, Oxycodone Controlled Release (CR), and/or Morphine Sustained Release (SR) (clinicaltrials.gov) - Dec 25, 2012
P4, N=150, Terminated, Sponsor: Janssen Scientific Affairs, LLC
Suspended --> Terminated; It was a business decision to cancel this study in Aug. 2012.
- ||||||| Palexia RP (tapentadol extended release) / Assertio, J&J, Grunenthal, Collegium Pharma
Trial completion: A Safety and Efficacy Study of JNS024 Extended Release (ER) in Japanese and Korean Patients With Chronic Malignant Tumor-Related Cancer Pain (clinicaltrials.gov) - Dec 16, 2012
P3, N=343, Completed, Sponsor: Janssen Research & Development, LLC
2012. Recruiting --> Completed
- | Palexia RP (tapentadol extended release) / Assertio, J&J, Grunenthal, Collegium Pharma
New P2 trial: A multi-center, randomized parallel group pilot study to investigate the mechanism of action of tapentadol PR and oxycodone CR in subjects with osteoarthritis knee pain (EUDRACT) - Nov 25, 2012
P2, N=60, Ongoing, Sponsor: C4Pain ApS
- morphine sulphate / Generic mfg., methadone / Generic mfg.
Trial termination: Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer (clinicaltrials.gov) - Nov 8, 2012
P=N/A, N=1, Terminated, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed Completed --> Terminated; Low Accrual.
- morphine sulphate / Generic mfg., methadone / Generic mfg.
Enrollment change: Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer (clinicaltrials.gov) - Nov 8, 2012
P=N/A, N=1, Terminated, Sponsor: M.D. Anderson Cancer Center
Completed --> Terminated; Low Accrual. N=300 --> 1
- | Troxyca ER (oxycodone/naltrexone) / Pfizer
Trial completion: A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers (clinicaltrials.gov) - Oct 21, 2012
P1, N=14, Completed, Sponsor: Pfizer
N=300 --> 1 Recruiting --> Completed
- ||||| cebranopadol (TRN-228) / Tris Pharma
New P2 trial: Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain (clinicaltrials.gov) - Oct 16, 2012
P2, N=600, Active, not recruiting, Sponsor: Forest Laboratories
- | oxycodone controlled release / Generic mfg., oxycodone/naloxone ER / Generic mfg.
New P4 trial: Opioidien aiheuttama mahasuolikanavan toiminnanhäiriö keisarileikkauspotilailla (EUDRACT) - Sep 12, 2012
P4, N=90, Ongoing, Sponsor: Merja Kokki
- | Troxyca ER (oxycodone/naltrexone) / Pfizer
New P1 trial: A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers (clinicaltrials.gov) - Aug 29, 2012
P1, N=14, Completed, Sponsor: Pfizer
- | Palexia RP (tapentadol extended release) / Assertio, J&J, Grunenthal, Collegium Pharma
New P4 trial: An Open-label Evaluation of Tapentadol Extended Release (ER) in Participants With Moderate to Severe Chronic Pain After Conversion From Hydrocodone, Oxycodone Controlled Release (CR), and/or Morphine Sustained Release (SR) (clinicaltrials.gov) - Jun 27, 2012
P4, N=150, Terminated, Sponsor: Janssen Scientific Affairs, LLC
- | Troxyca ER (oxycodone/naltrexone) / Pfizer
Trial completion: Pharmacokinetics Study of ALO-02 and OxyContin (clinicaltrials.gov) - Jun 25, 2012
P1, N=13, Completed, Sponsor: Pfizer
Recruiting --> Completed Recruiting --> Completed
- | oxycodone controlled release / Generic mfg.
Trial completion: A Open-label, Single-dose Study to Investigate The Pharmacokinetics Between a GL2907 XL and Oxycontin CR Tab. 10mg in Healthy Male Volunteers (clinicaltrials.gov) - Apr 21, 2012
P1, N=24, Completed, Sponsor: GL Pharm Tech Corporation
Recruiting --> Completed Recruiting --> Completed
- | oxycodone controlled release / Generic mfg.
New P1 trial: A Open-label, Single-dose Study to Investigate The Pharmacokinetics Between a GL2907 XL and Oxycontin CR Tab. 10mg in Healthy Male Volunteers (clinicaltrials.gov) - Mar 29, 2012
P1, N=24, Completed, Sponsor: GL Pharm Tech Corporation
- | Troxyca ER (oxycodone/naltrexone) / Pfizer
New P1 trial: Pharmacokinetics Study of ALO-02 and OxyContin (clinicaltrials.gov) - Mar 15, 2012
P1, N=13, Completed, Sponsor: Pfizer
- fulranumab (AMG-403) / Amgen
Enrollment change, Monotherapy: A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis (clinicaltrials.gov) - Feb 12, 2012
P2, N=196, Terminated, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting --> Completed N=300 --> 196
- | Nucynta (tapentadol) / Collegium Pharma, Grunenthal
Trial completion: Comparison of the Effects of Tapentadol and Oxycodone on Gastrointestinal and Colonic Transit in Humans (clinicaltrials.gov) - Jan 25, 2012
P4, N=38, Completed, Sponsor: Mayo Clinic
N=300 --> 196 Recruiting --> Completed
- morphine sulphate / Generic mfg., oxycodone controlled release / Generic mfg.
Trial termination, Surgery: Controlled-Release Oxycodone For Postoperative Analgesia After Video-Assisted Thoracic Surgery (clinicaltrials.gov) - Jan 4, 2012
P4, N=22, Terminated, Sponsor: University of Parma
Recruiting --> Completed Recruiting --> Terminated; Failure to enroll sufficient patients by expected deadline.
- morphine sulphate / Generic mfg., oxycodone controlled release / Generic mfg.
Enrollment change, Surgery: Controlled-Release Oxycodone For Postoperative Analgesia After Video-Assisted Thoracic Surgery (clinicaltrials.gov) - Jan 4, 2012
P4, N=22, Terminated, Sponsor: University of Parma
Recruiting --> Terminated; Failure to enroll sufficient patients by expected deadline. N=40 --> 22
- | Nucynta (tapentadol) / Collegium Pharma, Grunenthal
New P4 trial: Comparison of the Effects of Tapentadol and Oxycodone on Gastrointestinal and Colonic Transit in Humans (clinicaltrials.gov) - Dec 26, 2011
P4, N=38, Completed, Sponsor: Mayo Clinic
- | oxycodone controlled release / Generic mfg.
Trial completion: Pharmacokinetics and Safety of ORF Tablets in Pediatric Patients (clinicaltrials.gov) - Oct 13, 2011
P1, N=30, Completed, Sponsor: Purdue Pharma LP
N=40 --> 22 Recruiting --> Completed
- |||||||||| oxycodone controlled release / Generic mfg., oxycodone/naloxone ER / Generic mfg.
New P3 trial: A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain (clinicaltrials.gov) - Aug 30, 2011
P3, N=900, Recruiting, Sponsor: Purdue Pharma LP
- |||||||||| oxycodone controlled release / Generic mfg., oxycodone/naloxone ER / Generic mfg.
New P3 trial: Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain (clinicaltrials.gov) - Aug 30, 2011
P3, N=600, Recruiting, Sponsor: Purdue Pharma LP
- oxycodone controlled release / Generic mfg., lidocaine 5% / Generic mfg.
Enrollment change: Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis (clinicaltrials.gov) - Aug 16, 2011
P4, N=19, Terminated, Sponsor: University of Rochester
Recruiting --> Completed N=60 --> 19
- | fulranumab (AMG-403) / Amgen
Trial termination, Monotherapy: A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis (clinicaltrials.gov) - Aug 15, 2011
P2, N=196, Terminated, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
N=60 --> 19 Suspended --> Terminated; Logistic reasons associated with the FDA-imposed clinical hold.